{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:19:50Z","timestamp":1791825590727,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      To better understand the efficacy and safety of Bifidobacterium quadruple viable tablets in the treatment of\n                      <jats:italic>helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      )-infected peptic ulcer or gastritis patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic review of the studies published to June 2022 was performed in English database PubMed, Embase, Chinese database CNKI, Wanfang. There were 17 studies were included in this systematic review and meta-analysis. The outcomes measured included\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication rate, changes in clinical symptoms of epigastric pain scores, and the incidence of adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The results of the fixed effect model showed that the eradication rate of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      in the combination of Bifidobacterium quadruple viable bacteria tablets combined with bismuth-containing conventional quadruple therapy was greater than that of bismuth-containing conventional quadruple therapy, and the difference was statistically significant (OR\u2009=\u20093.73, 95%CI (2.79,5.00), Z\u2009=\u20092.78, P\u2009&lt;\u20090.001; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.0%, P\u2009&gt;\u20090.999). The results of random effects model showed that the epigastric pain score of Bifidobacterium quadruple viable bacteria tablets combined with bismuth-containing conventional quadruple therapy was lower than that of bismuth-containing conventional quadruple therapy, and the difference was statistically significant (WMD=-0.70, 95%CI (-1.06,-0.34), Z\u2009=\u20093.82, P\u2009&lt;\u20090.001; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200996.7%, P\u2009&lt;\u20090.001). The results of random effects model showed that the acid reflux score of Bifidobacterium quadruple viable bacteria tablets combined with bismuth-containing conventional quadruple therapy was lower than that of bismuth-containing conventional quadruple therapy, and the difference was statistically significant (WMD=-0.98, 95%CI (-1.70,-0.26), Z\u2009=\u20092.66, P\u2009&lt;\u20090.001; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200999.7%, P\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The eradication rate of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      by Bifidobacterium quadruple viable bacteria tablets combined with bismuth-containing quadruple therapy is better than that of bismuth-containing quadruple therapy. The improvement of clinical symptoms of patients is better than that of bismuth-containing quadruple therapy, and the incidence of adverse reactions is lower than that of bismuth-containing quadruple therapy. Bifidobacterium quadruple viable bacteria tablet combined with bismuth-containing quadruple therapy was effective and safe. It provides a new way to treat patients with\n                      <jats:italic>H. pylori<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08211-1","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T03:31:40Z","timestamp":1683689500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Xueliang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"Suppl 1","key":"8211_CR1","first-page":"32","volume":"22","author":"V Camilo","year":"2017","unstructured":"Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017;22(Suppl 1):32\u20135.","journal-title":"Helicobacter"},{"key":"8211_CR2","doi-asserted-by":"publisher","first-page":"356217","DOI":"10.1155\/2013\/356217","volume":"2013","author":"CH Lai","year":"2013","unstructured":"Lai CH, Perng CL, Lan KH, Lin HJ. Association of IS605 and cag-PAI of Helicobacter pylori isolated from patients with gastrointestinal Diseases in Taiwan. Gastroenterol Res Pract. 2013;2013:356217.","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"8211_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10096-010-0881-7","volume":"29","author":"HM Schmidt","year":"2010","unstructured":"Schmidt HM, Andres S, Nilsson C, Kovach Z, Kaakoush NO, Engstrand L, Goh KL, Fock KM, Forman D, Mitchell H. The cag PAI is intact and functional but HP0521 varies significantly in Helicobacter pylori isolates from Malaysia and Singapore. Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol. 2010;29(4):439\u201351.","journal-title":"Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol"},{"issue":"1","key":"8211_CR4","first-page":"18","volume":"101","author":"SM Sheu","year":"2002","unstructured":"Sheu SM, Sheu BS, Yang HB, Li C, Chu TC, Wu JJ. Presence of iceA1 but not cagA, cagC, cagE, cagF, cagN, cagT, or orf13 genes of Helicobacter pylori is associated with more severe gastric inflammation in taiwanese. J Formos Med Association = Taiwan yi zhi. 2002;101(1):18\u201323.","journal-title":"J Formos Med Association = Taiwan yi zhi"},{"issue":"4","key":"8211_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3748\/wjg.v10.i4.602","volume":"10","author":"CL Perng","year":"2004","unstructured":"Perng CL, Lin HJ, Lo WC, Tseng GY, Sun IC, Ou YH. Genotypes of Helicobacter pylori in patients with peptic ulcer bleeding. World J Gastroenterol. 2004;10(4):602\u20135.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"8211_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0732-8893(03)00034-8","volume":"46","author":"RP Podzorski","year":"2003","unstructured":"Podzorski RP, Podzorski DS, Wuerth A, Tolia V. Analysis of the vacA, cagA, cagE, iceA, and babA2 genes in Helicobacter pylori from sixty-one pediatric patients from the midwestern United States. Diagn Microbiol Infect Dis. 2003;46(2):83\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"8211_CR7","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1111\/j.1572-0241.2002.05977.x","volume":"97","author":"PI Hsu","year":"2002","unstructured":"Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, Kim JG, Osato MS, Graham DY, Yamaoka Y. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol. 2002;97(9):2231\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"25","key":"8211_CR8","first-page":"429","volume":"115","author":"W Fischbach","year":"2018","unstructured":"Fischbach W, Malfertheiner P. Helicobacter Pylori infection. Deutsches Arzteblatt international. 2018;115(25):429\u201336.","journal-title":"Deutsches Arzteblatt international"},{"issue":"1","key":"8211_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ijc.11680","volume":"109","author":"H Ohata","year":"2004","unstructured":"Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109(1):138\u201343.","journal-title":"Int J Cancer"},{"issue":"8477","key":"8211_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(86)92353-6","volume":"1","author":"R Hill","year":"1986","unstructured":"Hill R, Pearman J, Worthy P, Caruso V, Goodwin S, Blincow E. Campylobacter pyloridis and gastritis in children. Lancet (London England). 1986;1(8477):387.","journal-title":"Lancet (London England)"},{"issue":"1","key":"8211_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10096-018-3414-4","volume":"38","author":"P Sabbagh","year":"2019","unstructured":"Sabbagh P, Mohammadnia-Afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol. 2019;38(1):55\u201366.","journal-title":"Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol"},{"key":"8211_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.micpath.2018.02.016","volume":"117","author":"S Nejati","year":"2018","unstructured":"Nejati S, Karkhah A, Darvish H, Validi M, Ebrahimpour S, Nouri HR. Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. Microb Pathog. 2018;117:43\u20138.","journal-title":"Microb Pathog"},{"issue":"1","key":"8211_CR13","first-page":"163","volume":"7","author":"S Tokudome","year":"2006","unstructured":"Tokudome S, Hosono A, Suzuki S, Ghadimi R, Tanaka T, Ichikawa H, Miyata M, Marumoto M, Agawa H, Arakawa K, et al. Helicobacter pylori infection as an essential factor for stomach cancer. Asian Pac J cancer prevention: APJCP. 2006;7(1):163.","journal-title":"Asian Pac J cancer prevention: APJCP"},{"issue":"9","key":"8211_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jamapediatrics.2022.1973","volume":"176","author":"J Lukasik","year":"2022","unstructured":"Lukasik J, Dierikx T, Besseling-van der Vaart I, de Meij T, Szajewska H. Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: a Randomized Clinical Trial. JAMA Pediatr. 2022;176(9):860\u20136.","journal-title":"JAMA Pediatr"},{"issue":"4","key":"8211_CR15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ajcn\/83.4.864","volume":"83","author":"BS Sheu","year":"2006","unstructured":"Sheu BS, Cheng HC, Kao AW, Wang ST, Yang YJ, Yang HB, Wu JJ. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr. 2006;83(4):864\u20139.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"8211_CR16","first-page":"115","volume":"26","author":"SS Yildiz","year":"2018","unstructured":"Yildiz SS, Yalinay M, Karakan T. Bismuth-based quadruple Helicobacter pylori eradication regimen alters the composition of gut microbiota. Le Infezioni in Medicina. 2018;26(2):115\u201321.","journal-title":"Le Infezioni in Medicina"},{"key":"8211_CR17","doi-asserted-by":"crossref","unstructured":"He C, Kong F, Chai X, Zou C, Zhu X, Zhao D. Effect of Probiotic-Assisted Eradication of cagA+\/vacA s1m1 Helicobacter pylori on Intestinal Flora. BioMed research international 2022, 2022:8607671.","DOI":"10.1155\/2022\/8607671"},{"issue":"2","key":"8211_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.23736\/S1121-421X.19.02651-5","volume":"66","author":"F Di Pierro","year":"2020","unstructured":"Di Pierro F, Bertuccioli A, Saponara M, Ivaldi L. Impact of a two-bacterial-strain formula, containing Bifidobacterium animalis lactis BB-12 and Enterococcus faecium L3, administered before and after therapy for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2020;66(2):117\u201323.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"8211_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13099-016-0091-7","volume":"8","author":"P Nagy","year":"2016","unstructured":"Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut pathogens. 2016;8:8.","journal-title":"Gut pathogens"},{"issue":"10","key":"8211_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","volume":"2","author":"YT Kuo","year":"2017","unstructured":"Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. lancet Gastroenterol Hepatol. 2017;2(10):707\u201315.","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"10","key":"8211_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1473-3099(19)30272-5","volume":"19","author":"JM Liou","year":"2019","unstructured":"Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19(10):1109\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"8211_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/00029330-200705020-00014","volume":"120","author":"JG Lou","year":"2007","unstructured":"Lou JG, Chen J, Huang XL, Zhao ZY. Changes in the intestinal microflora of children with Helicobacter pylori infection and after Helicobacter pylori eradication therapy. Chin Med J. 2007;120(10):929\u201331.","journal-title":"Chin Med J"},{"issue":"5","key":"8211_CR23","doi-asserted-by":"publisher","first-page":"e12721","DOI":"10.1111\/hel.12721","volume":"25","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Ye Z, Lu J, Miao S, Lu X, Sun H, Wu J, Wang Y, Huang Y. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter. 2020;25(5):e12721.","journal-title":"Helicobacter"},{"issue":"9","key":"8211_CR24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1046\/j.1365-2036.2002.01335.x","volume":"16","author":"BS Sheu","year":"2002","unstructured":"Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16(9):1669\u201375.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"8211_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00431-018-3282-z","volume":"178","author":"HR Fang","year":"2019","unstructured":"Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatrics. 2019;178(1):7\u201316.","journal-title":"Eur J Pediatrics"},{"issue":"1","key":"8211_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MCG.0b013e318266f6cf","volume":"47","author":"ZH Wang","year":"2013","unstructured":"Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25\u201332.","journal-title":"J Clin Gastroenterol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08211-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T03:36:18Z","timestamp":1683689778000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8211"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08211-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"313"}}